Lactoferrin regulates the immune responses in post-surgical patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 4, 2001, Pages 325-333

  Zimecki, Michał ^a   Właszczyk, Andrzej ^b   Wojciechowski, Robert ^b   Dawiskiba, Janusz ^b   Kruzel, Marian ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Clinical insult; Immunoregulation; Lactoferrin; Prevention

Indexed keywords

INTERLEUKIN 6; LACTOFERRIN; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NEUTROPHIL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT; THYROID SURGERY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; BLOOD CELL COUNT; BLOOD CELLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; LACTOFERRIN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; POSTOPERATIVE COMPLICATIONS; THYROID DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0343288991     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ABRAHAM E. (2000): Cytokine neutralization. An overview. In: MARSHALL J. C., COHEN J. (eds.): Immune response in the critically ill. Springer, Heidelberg, 385-392.
2. ADAMIK B., ZIMECKI M., WŁASZCZYK A., BEREZOWICZ P. and KÜBLER A. (1998): Lactoferrin effects on the in vitro immune response in critically ill patients. Arch. Immunol. Ther. Exp., 46, 169-176.
3. ASIMAKOPOULOS G. (1999): Mechanisms of the systemic inflammatory response. Perfusion, 14, 269-277.
4. BAGGIELINI M., DE DUVE C., MASSON P. L. and HERMANS J. F. (1970): Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J. Exp. Med., 131, 559-570.
5. BENNETT R. M. and KOKOCINSKI T. (1979): Lactoferrin turnover in man. Clin. Sci., 57, 453-460.
6. BEUTLER B. (1995): TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med., 43, 227-235.
7. BODE C., FUKUI H. and BODE J. C. (1993): Hidden endotoxin plasma of patients with alcoholic liver disease. Eur. J. Gastroenterol. Hepatol., 5, 257-262.
8. BROCK J. (1995): Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today, 16, 417-419.
9. CROUCH S. P. M., SLATER K. J. and FLETCHER J. (1992): Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood, 80, 235-240.
10. DEBBABI H., DUBARRY M., RAUTUREAU M. and TOMÉ D. (1998): Bovine lactoferrin induces both mucosal and systemic immune response in mice. J. Dairy Res., 65, 283-293.
11. DIXON J. M., ARMSTRONG C. P., DUFFY S. W. and DAVIES G. C. (1983): Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut, 24, 845-852.
12. ESPEVIK T. and NISSEN-MEYER J. (1986): A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxin factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95, 99-105.
13. GEBHARD F., KAFFENBERGER W. and HARTEL W. (1994): Peripheral blood immune responses to surgically induced lung tissue injury. Eur. Surg. Res., 26, 156-162.
14. HANSEN M. B., NIELSEN S. E. and BERG K. (1989): Reexamination and further development of a precise and rapid dye method for measuring cell growth/kill. J. Immunol. Methods, 119, 203-210.
15. HAVEL E. A. (1989): Evidence that tumor necrosis factor has an important role in antibacterial resistance. J. Immunol., 143, 2894-2899.
16. HENSLER T., HECKER H., HEEG K., HEIDECKE C.-D., BARTELS H., BARTHLEN W., WAGNER H., SIEWERT J.-R. and HOLZMAN B. (1997): Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect. Immun., 65, 2283-2291.
17. HOUDIJK A. P., MEIJER C., CUESTA M. A., MEYER S. and VAN LEEUVEN P. A. M. (1997): Perioperative anti-endotoxin strategies. Scand. J. Gastroenterol., 32, 93-97.
18. HU W. L., MAZURIER J., MONTREUIL J. and SPIK G. (1990): Isolation and partial characterization of a lactoferrin receptor from mouse intestinal brush border. Biochemistry, 29, 235-241.
19. JOHNSTONE M. T., CREAGER S. J., SCALES K. M., CUSCO J. A., LEE B. K. and CREAGER M. A. (1993): Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes melitus. Circulation, 88, 2510-2516.
20. KOIKE D. and MAKINO I. (1993): Protective effect of lactoferrin on cearulein-induced acute pancreatitis in rats. Digestion, 54, 84-90.
21. KRUZEL M. L., HAVARI Y., CHEN C.-Y. and CASTRO G. A. (2000): Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation, 24, 33-44.
22. LEMAIRE L. C. J. M., VAN DER POLL T., VAN LANSCHOT J. J. B., ENDERT E., BUURMAN W. A., VAN DEVENTER S. J. H. and GOUMA D. J. (1998): Minimally invasive surgery induces endotoxin-tolerance in the absence of detectable endotoxemia. J. Clin. Immunol., 18, 414-420.
23. LIVINGSTON D. H., APPERL S. H., WELLHAUSEN S. R., SONNENFELD G. and POLK H. C. JR. (1988): Depressed interferon-γ production and monocyte HLA-DR expression after severe injury. Arch. Surg., 123, 1309-1312.
24. LOUIS E., FRANCHIMOUT D., PIRON A., GEVAERT Y., SCHAAF-LAFONTAINE N., ROLAND S., MACHIEU P., MALAISE M., DE GROOTE D., LOUIS R. and BELAICHE J. (1998): Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol., 113, 401-409.
25. LÖNNERDAL B. and IYER S. (1995): Lactoferrin: molecular structure and biological function. Ann. Rev. Nutr., 15, 93-110.
26. MACHNICKI M., ZIMECKI M. and ZAGULSKI T. (1993): Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol., 74, 433-439.
27. PITTET D., RANGEL-FRAUSTO S., LI N., TARARA D., COSTIGAN M., REMPE L., JESEN D. and WENZEL R. P. (1995): Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med., 21, 302-309.
28. RICH I. N. (1998): The macrophage as a production site for hematopoietic regulator molecule: sensing and responding to normal and pathophysiological signals. Anticancer Res., 8, 1015-1040.
29. ROUMEN R. M., HENDRIKS T., VAN DER VEN JONGERKRIJG J., NIEUWENHUIJZEN G. A., SANERWEIN R. W., VAN DER MEER J. W. and GORIS R. J. (1993): Cytokine patterns in patients after major vascular surgery, hemorrhagic shock and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann. Surg., 218, 768-776.
30. SALO M. (1978): Effect of anaesthesia and surgery on the number of and mitogen induced transformation of T-and B-lymphocytes. Ann. Clin. Res., 10, 1-13.
31. SALO M. (1992): Effects of anaesthesia and surgery and the immune response. Acta Anaesthesiol. Scand., 36, 201-220.
32. SPIK G., BRUNET B., MAZURIER-DEHAINE C., FONTAINE G. and MONTREUIL J. (1982): Characterization and properties of the human and bovine lactotransferrins extracted from the faeces of newborn infants. Acta Paediatr. Scand., 71, 979-985.
33. TOMITA M., YAMAMUCHI K., TERAGUCHI S. and HAYASAWA H. (1998): Host defensive effects of orally administered bovine lactoferrin. Adv. Exp. Med. Biol., 443, 189-197.
34. 2-terminal amino acid sequence of a T cell-derived lymphokine with growth factor activity for B cell hybridomas. Proc. Natl. Acad. Sci., USA, 83, 9679-9683.
35. WILKINSON S. P., MOODIE H., STAMATAKIS J. D., KAKKER V. V. and WILIAMS R. (1976): Endotoxemia and renal failure in cirrhosis and obstructive jaundice. Br. Med. J., 2, 1415-1418.
36. WŁASZCZYK A., ADAMIK B., DUREK G., KÜBLER A. and ZIMECKI M. (1996): Immunological status of patients subjected to cardiac surgery: serum levels of interleukin 6 and tumor necrosis factor and the ability of peripheral blood mononuclear cells to proliferate and produce these cytokines in vitro. Arch. Immunol. Ther. Exp., 44, 225-234.
37. WŁASZCZYK A., ZIMECKI M., ADAMIK B., DUREK G. and KÜBLER A. (1997): Immunological status of patients subjected to cardiac surgery: Effect of lactoferrin on proliferation and production of interleukin 6 and tumor necrosis factor a by peripheral blood mononuclear cells in vitro. Arch. Immunol. Ther. Exp., 45, 201-212.
38. WRIGHT D. G. (1982): The neutrophil as a secretory organ of host defense. In GALLIN J. I. and FANCI A. S. (eds.): Advances in host defense mechanisms. Raven Press, New York, 1, 75-110.
39. ZAGULSKI T., LIPIŃSKI P., ZAGULSKA A., BRONIAREK S. and JARZA̧BEK Z. (1989): Lactoferrin can protect mice against a lethal dose of Escherichia coli. Int. J. Exp. Pathol., 70, 697-704.
40. ZHANG G.-H., MANN D. M. and TSAI C.-M. (1999): Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect. Immun., 67, 1353-1358.
41. ZIMECKI M. and KRUZEL M. (2000): Protective effect of lactoferrin against LPS-induced endotoxemia is mediated by IL-10. 5th World Congress on Trauma, Shock, Inflammation and Sepsis, February 29-March 4, 2000, Munich (Germany). Monduzzi Editore, 221-225.
42. ZIMECKI M. and KRUZEL M. (2000): Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivily in mice. Immunol. Lett., 74, 183-188.
43. ZIMECKI M., MAZURIER J., MACHNICKI M., WIECZOREK Z., MONTREUIL J. and SPIK G. (1991): Immunostimulatory activity of lactotransferrin and maturation of CD4, CD8 thymocytes. Immunol. Lett., 30, 119-124.
44. ZIMECKI M., MAZURIER J., SPIK G. and KAPP A. J. (1995): Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 86, 122-127.
45. ZIMECKI M., MAZURIER J., SPIK G. and KAPP J. A. (1996): Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch. Immunol. Ther. Exp., 46, 97-104.
46. ZIMECKI M., MIȨDZYBRODZKI R., MAZURIER J. and SPIK G. (1999): Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch. Immunol. Ther. Exp., 47, 257-264.
47. ZIMECKI M., SPIEGEL K., WŁASZCZYK A., KÜBLER A. and KRUZEL M. L. (1999): Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-α and IL-6 by peripheral blood cells. Arch. Immunol. Ther. Exp., 47, 113-118.
48. ZIMECKI M., WŁASZCZYK A., CHENEAU P., BRUNEL A., MAZURIER A., SPIK G. and KUBLER A. (1998): Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals. Arch. Immunol. Ther. Exp., 46, 231-240.
49. ZIMECKI M., WŁASZCZYK A., ZAGULSKI T. and KÜBLER A. (1998): Lactoferrin lowers serum interleukin 6 and tumor necrosis factor a levels in mice subjected to surgery. Arch. Immunol. Ther. Exp., 46, 97-104.